Korean J healthc assoc Infect Control Prev.  2021 Jun;26(1):3-15. 10.14192/kjicp.2021.26.1.3.

Preparing for COVID-19 Vaccination: Guidelines for Healthcare Personnel

• Kim YR
• Kim DJ
• Choi YH

• KMID: 2516939
• DOI: http://doi.org/10.14192/kjicp.2021.26.1.3

Abstract

In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a pandemic. Given the urgent need for vaccines against COVID-19, huge financial investments and global scientific collaborations have been made to develop effective and safe vaccines. To date, WHO has included five COVID-19 vaccines, comprising BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), AZD1222 (AstraZeneca), Ad26.COV2.S (Johnson and Johnson’s Janssen), and BBIBP-CorV (Sinopharm) under WHO Emergency Use Listing as they are considered to meet the necessary criteria for safety and efficacy. In Korea, the Pfizer-BioNTech vaccine and AstraZeneca vaccine have been administered since February 2021, and three more COVID-19 vaccines are scheduled for incorporation till the end of 2021. This article focuses on the clinical and technical considerations of COVID-19 vaccinations to provide accurate and safe guidance for healthcare practitioners. A brief review of COVID-19 vaccines to be introduced in Korea is also summarized.

Keyword

COVID-19; COVID-19 vaccines; COVID-19 pandemics

Reference

1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. 2020; The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 5:536–44. DOI: 10.1038/s41564-020-0695-z. PMID: 32123347. PMCID: PMC7095448.

2. WHO. WHO coronavirus (COVID-19) dashboard. https://covid19.who.int/?.gclid=EAIaIQobChMI6Omu7pLJ8AIVjF1gCh1vLwmmEAAYASABEgItPfD_BwE . Updated on 25 May 2021.

3. WHO. COVID-19 vaccine tracker. https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/ . Updated on 24 May 2021.

4. CDC. Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States. https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html . Updated on 14 May 2021.

5. CDC. Vaccine storage and handling toolkit. https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html . Updated on March 2021.

6. U.S. Food and Drug Administration. Fact sheet for healthcare providers administering vaccine. Emergency Use Authorization (EUA) of the Pfizer-BioNTeCH COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19). https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine . Updated on 19 May 2021.

7. U.S. Food and Drug Administration. Fact sheet for healthcare providers administering vaccine (vaccination providers). Emergency Use Authorization (EUA) of the Moderna COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19). https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine . Updated on 31 March 2021.

8. U.S. Food and Drug Administration. Fact sheet for healthcare providers administering vaccine (vaccination providers). Emergency Use Authorization (EUA) of the Janssen COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19). https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine#additional . Updated on 23 April 2021.

9. , Medicines and Healthcare products Regulatory Agency, UK Department of Health and Social Care. Regulatory approval of COVID-19 Vaccine AstraZeneca. Regulatory approval of COVID-19 Vaccine AstraZeneca. https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca . Updated on 15 April 2021.

10. Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, et al. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. N Engl J Med. in press 2021.

11. CDC. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html . Updated on 4 May 2021.

12. CDC. Screen for contraindications and precautions. https://www.cdc.gov/vaccines/hcp/admin/screening.html . Updated on 7 May 2019.

13. CDC. Prevaccination checklist for COVID-19 vaccines. https://www.cdc.gov/vaccines/covid-19/downloads/pre-vaccination-screening-form.pdf . Updated on 27 May 2021.

14. Novavax. Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK Phase 3 Trial. https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3 . Updated on 28 January 2021.

15. Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et al. 2021; Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 384:1899–909. DOI: 10.1056/NEJMoa2103055. PMID: 33951374. PMCID: PMC8091623.

16. CDC. COVID-19 vaccine training: general overview of immunization best practices for healthcare providers. https://www2.cdc.gov/vaccines/ed/covid19/SHVA/30010 . Updated on 19 November 2020.

17. Public Health England. COVID-19 vaccination programme: information for healthcare practitioners. COVID-19 vaccination programme: information for healthcare practitioners. https://www.gov.uk/government/publications/covid-19-vaccination-programme-guidance-for-healthcare-practitioners . Updated on 9 June 2021.

18. CDC. Vaccine administration: intramuscular (IM) injection adults 19 years of age and older. https://www.cdc.gov/vaccines/covid-19/hcp/faq.html . Updated on 16 November 2020.

19. Minnesota Department of Health. Interim COVID-19 vaccine provider guide. https://www.health.state.mn.us/diseases/coronavirus/vaccine/provider.html . Updated on 27 May 2021.

20. Parry H, Bruton R, Stephens C, Brown K, Amirthalingam G, Hallis B, et al. 2021. Extended interval BNT162b2 vaccination enhances peak antibody generation in older people. MedRxiv. 21257017. [Preprint] Available from: https://doi.org/10.1101/2021.05.15. 21257017. [cited 2021 May 30]. DOI: 10.1101/2021.05.15.21257017.

21. European Medicines Agency. Summary of product characteristics. Summary of product characteristics. https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-janssen . Updated on 7 May 2021.

22. Public Health England. COVID-19: the green book, chapter 14a. COVID-19: the green book, chapter 14a. https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a . Updated on 7 May 2021.

23. European Medicines Agency. COVID-19 vaccine safety update: Vaxzevria AstraZeneca AB. COVID-19 vaccine safety update: Vaxzevria AstraZeneca AB. https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria-previously-covid-19-vaccine-astrazeneca#safety-updates-section . Updated on 21 May 2021.

24. Kim L, Garg S, O'Halloran A, Whitaker M, Pham H, Anderson EJ, et al. 2021; Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). Clin Infect Dis. 72:e206–14. DOI: 10.1093/cid/ciaa1012. PMID: 32674114. PMCID: PMC7454425.

25. Geretti AM, Stockdale AJ, Kelly SH, Cevik M, Collins S, Waters L, et al. Outcomes of coronavirus disease 2019 (COVID-19) related hospitalization among people with human immunodeficiency virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): a prospective observational study. Clin Infect Dis. in press 2020. DOI: 10.1093/cid/ciaa1605. PMID: 33095853. PMCID: PMC7665382.

26. Clinical Info HIV.gov. Interim guidance for COVID-19 and persons with HIV. https://clinicalinfo.hiv.gov/en/guidelines/covid-19-and-persons-hiv-interim-guidance/interim-guidance-covid-19-and-persons-hiv . Updated on 26 February 2021.

27. Tesoriero JM, Swain CE, Pierce JL, Zamboni L, Wu M, Holtgrave DR, et al. 2021; COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York State. JAMA Netw Open. 4:e2037069. DOI: 10.1001/jamanetworkopen.2020.37069. PMID: 33533933. PMCID: PMC7859843.

28. Fung M, Babik JM. 2021; COVID-19 in immunocompromised hosts: what we know so far. Clin Infect Dis. 72:340–50. DOI: 10.1093/cid/ciaa863. PMID: 33501974. PMCID: PMC7337668.

29. The Transplantation Society. TID COVID-19 guidance focused review: SARS-CoV-2 vaccines in transplant recipients. TID COVID-19 guidance focused review: SARS-CoV-2 vaccines in transplant recipients. https://tts.org/26-tid/tid-resources/850-tid-covid-19-guidance-focused-review-sars-cov-2-vaccines-in-transplant-recipients . Updated on 1 March 2021.

30. Park JK, Lee EB, Shin K, Sung YK, Kim TH, Kwon SR, et al. 2021; COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: clinical guidance of the Korean College of Rheumatology. J Korean Med Sci. 36:e95. DOI: 10.3346/jkms.2021.36.e95. PMID: 33783147. PMCID: PMC8007420.

31. Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, et al. , El Burai Felix S. 2020; Coronavirus disease 2019 case surveillance - United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep. 69:759–65. DOI: 10.15585/mmwr.mm6924e2. PMID: 32555134. PMCID: PMC7302472.

32. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. 2020; Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 369:m1985. DOI: 10.1136/bmj.m1985. PMID: 32444460. PMCID: PMC7243036.

33. Chirico F, Nucera G, Magnavita N. 2020; COVID-19: protecting healthcare workers is a priority. Infect Control Hosp Epidemiol. 41:1117. DOI: 10.1017/ice.2020.148. PMID: 32299519. PMCID: PMC7198459.

34. Korean Society of Medical Oncology. Preliminary guideline of COVID-19 vaccination in Korean cancer patients. Preliminary guideline of COVID-19 vaccination in Korean cancer patients. https://www.ksmo.or.kr/ . Updated on 7 April 2021.

35. National Comprehensive Cancer Network. NCCN: cancer and COVID-19 vaccination. NCCN: cancer and COVID-19 vaccination. https://www.nccn.org/covid-19#Best-Practices-COVID-19 . Updated on 10 March 2021.

36. Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, Alaguthurai T, et al. , Del Molino Del Barrio I. 2021; Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 22:765–78. DOI: 10.1016/S1470-2045(21)00213-8.

37. Srivatana V, Wilkie C, Perl J, Watnick S. Vaccine and the need to be heard: considerations for COVID-19 immunization in ESKD. Kidney360. in press 2021. DOI: 10.34067/KID.0001932021.

38. The Korean Society of Nephrology. Recommendation on COVID-19 Vaccination for dialysis patients. Recommendation on COVID-19 Vaccination for dialysis patients. http://www.ksn.or.kr/ . Updated on 3 May 2021.

39. CDC. Vaccinating dialysis patients and healthcare personnel. https://www.cdc.gov/vaccines/covid-19/planning/vaccinate-dialysis-patients-hcp.html . Updated on 24 March 2021.

40. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. 2020; Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 586:589–93. DOI: 10.1038/s41586-020-2639-4. PMID: 32785213.

41. Shaw RH, Stuart A, Greenland M, Liu X, Van-Tam JSN, Snape MD. 2021; Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 397:2043–6. DOI: 10.1016/S0140-6736(21)01115-6.

42. Janssen Scientific Affairs. Janssen COVID-19 Vaccine - stability - temperature excursion (vials). Janssen COVID-19 Vaccine - stability - temperature excursion (vials). https://www.janssenmd.com/janssen-covid19-vaccine/interactive-content/stability-information . Updated on 5 May 2021.

43. WHO Regional Office for the Western Pacific. 2015. Immunization safety surveillance: guidelines for immunization programme managers on surveillance of adverse events following immunization. 3rd ed. WHO Regional Office for the Western Pacific;Manila: p. 23–30.

44. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. 2021; Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 397:99–111. DOI: 10.1016/S0140-6736(20)32661-1.

45. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. 2020; Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 383:2603–15. DOI: 10.1056/NEJMoa2034577. PMID: 33301246. PMCID: PMC7745181.

46. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. in press 2021. DOI: 10.1056/NEJMoa2101544. PMID: 33882225.

47. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. 2021; Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 384:403–16. DOI: 10.1056/NEJMoa2035389. PMID: 33378609. PMCID: PMC7787219.

48. Shimabukuro T, Nair N. 2021; Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. JAMA. 325:780–1. DOI: 10.1001/jama.2021.0600. PMID: 33475702.

49. Shimabukuro TT, Cole M, Su JR. 2021; Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021. JAMA. 325:1101–2. DOI: 10.1001/jama.2021.1967. PMID: 33576785.

50. Food and Drug Administration. Food and Drug Administration. 2021; Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021. MMWR Morb Mortal Wkly Rep. 70:125–9. DOI: 10.15585/mmwr.mm7004e1. PMID: 33507892. PMCID: PMC7842812.

51. Resuscitation Council UK. Emergency treatment of anaphylaxis: guidelines for healthcare providers. Emergency treatment of anaphylaxis: guidelines for healthcare providers. https://www.resus.org.uk/library/additional-guidance/guidance-anaphylaxis/emergency-treatment . Updated on May 2021.

52. Resuscitation Council UK. Management of anaphylaxis in the vaccination setting. Management of anaphylaxis in the vaccination setting. https://www.resus.org.uk/about-us/news-and-events/rcuk-publishes-anaphylaxis-guidance-vaccination-settings . Updated on December 2020.

53. Korea Disease Control and Prevention Agency. Monthly safety report after COVID-19 vaccination. https://ncv.kdca.go.kr/board.es?.mid=a11707010000&bid=0032#content . Updated on 17 May 2021.

54. European Medicines Agency. AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood . Updated on 7 April 2021.

55. European Medicines Agency. Signal assessment report on Embolic and Thrombotic events (SMQ) with COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]). https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-report-embolic-thrombotic-events-smq-covid-19-vaccine-janssen-ad26cov2-s_en.pdf . Updated on 20 April 2021.

56. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. 2021; Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 384:2092–101. DOI: 10.1056/NEJMoa2104840. PMID: 33835769. PMCID: PMC8095372.

57. Medicines and Healthcare products Regulatory Agency. Coronavirus vaccine - weekly summary of Yellow Card reporting. Coronavirus vaccine - weekly summary of Yellow Card reporting. https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting . Updated on 3 June 2021.

58. Mahase E. 2021; AstraZeneca vaccine: blood clots are "extremely rare" and benefits outweigh risks, regulators conclude. BMJ. 373:n931. DOI: 10.1136/bmj.n931. PMID: 33832929.

59. Korea Disease Control and Prevention Agency. Medical expenses for severely ill patients after COVID-vaccination exempted from compensation due to the lack of causality. Medical expenses for severely ill patients after COVID-vaccination exempted from compensation due to the lack of causality. http://ncov.mohw.go.kr/tcmBoardView.do?.brdId=3&brdGubun=31&dataGubun=&ncvContSeq=5387&contSeq=5387&board_id=312&gubun=ALL . Updated on 17 May 2021.

60. Amiral J, Vissac AM. Kelleni M, editor. Update on mechanisms, pathogenicity, heterogeneity of presentation, and laboratory diagnosis of heparin-induced thrombocytopenia. Anticoagulation drugs - the current state of the art. IntechOpen;London: p. 27–34. DOI: 10.5772/intechopen.86475. PMCID: PMC7252011.

61. Pai M, Schull M, Razak F, Grill A, Ivers N, Maltsev A, et al. Vaccine-induced prothrombotic immune thrombocytopenia VIPIT following AstraZeneca COVID-19 vaccination: interim guidance for healthcare professionals in emergency department and inpatient settings. Sci Briefs Ont COVID-19 Sci Advis Table 2021. doi: 10.47326/ocsat.2021.02.21.1.0.DOI: 10.47326/ocsat.2021.02.21.1.0. PMCID: PMC8117624.